The long fight to end HIV/AIDS has seen real progress spurred by innovative research, prevention, treatment and education. But our nation’s ambitious goal of ending the HIV epidemic by 2030 is nevertheless in peril. Here are ways to step up the fight.
Read More
An experimental HIV vaccine has been found to induce broadly neutralizing antibody precursors among a small group of volunteers in a Phase 1 study. The findings suggest that a two-dose regimen of the vaccine, given eight weeks apart, can elicit immune responses against the human immunodeficiency virus.
Read More
Drug giant GlaxoSmithKline earned two victories in the ongoing battle to treat AIDS, one involving a patent settlement and the other securing FDA approval for a long-term HIV treatment from GSK-owned ViiV Healthcare.
Read More
The US Food and Drug Administration has approved the first injectable medication for pre-exposure prophylaxis (PrEP) to lower the risk of getting HIV through sex, it announced Monday. And the drug has roots in North Carolina,
Read More
The National Institutes of Health has awarded approximately $53 million in annual funding over the next five years to 10 research organizations in a continued effort to find a cure for HIV. UNC-CH is among the recipients.
Read More
Ed Browne, PhD, assistant professor of medicine, is the principal investigator of a $4-million, 5-year study of the role of cannabis use in HIV latency – one of the main barriers toward curing people with the infection.
Read More
U.S. regulators have approved the first long-acting drug combo for HIV, monthly shots that can replace the daily pills now used to control infection with the AIDS virus.
Read More
ViiV Healthcare, which has a major presence in RTP, has secured European Union approval for its once-a-month treatment of HIV, offering an alternative to daily care.
Read More
An injectable drug from ViiV Healthcare has proved to be much more effective in preventing HIV among women than a currently daily pill treatment, ViiV announced early Monday.
Read More
